The Chemours Company $CC Shares Sold by Bryce Point Capital LLC

Bryce Point Capital LLC trimmed its position in shares of The Chemours Company (NYSE:CC) by 50.1% during the third quarter, Holdings Channel reports. The firm owned 41,661 shares of the specialty chemicals company’s stock after selling 41,768 shares during the quarter. Chemours makes up approximately 0.8% of Bryce Point Capital LLC’s portfolio, making the stock its 14th biggest holding. Bryce Point Capital LLC’s holdings in Chemours were worth $660,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. MTM Investment Management LLC purchased a new stake in shares of Chemours in the 2nd quarter valued at $27,000. Evelyn Partners Asset Management Ltd acquired a new position in Chemours in the 2nd quarter valued at about $37,000. FNY Investment Advisers LLC increased its stake in Chemours by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 4,000 shares of the specialty chemicals company’s stock worth $45,000 after purchasing an additional 2,000 shares during the period. CWM LLC increased its stake in Chemours by 34.7% during the second quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company’s stock worth $49,000 after purchasing an additional 1,104 shares during the period. Finally, Hantz Financial Services Inc. lifted its position in shares of Chemours by 334.2% during the third quarter. Hantz Financial Services Inc. now owns 4,329 shares of the specialty chemicals company’s stock worth $69,000 after purchasing an additional 3,332 shares in the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Mizuho cut their price target on Chemours from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, October 16th. Weiss Ratings restated a “sell (d)” rating on shares of Chemours in a research note on Wednesday, January 21st. Truist Financial lifted their price target on shares of Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, January 21st. Royal Bank Of Canada reissued an “outperform” rating and issued a $18.00 price objective on shares of Chemours in a research report on Friday, January 16th. Finally, UBS Group decreased their price objective on shares of Chemours from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, November 11th. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Chemours currently has an average rating of “Hold” and an average target price of $16.67.

Chemours Stock Performance

NYSE CC opened at $18.97 on Tuesday. The company has a market capitalization of $2.84 billion, a PE ratio of -8.55 and a beta of 1.63. The company has a debt-to-equity ratio of 13.66, a current ratio of 1.71 and a quick ratio of 0.88. The Chemours Company has a 1 year low of $9.13 and a 1 year high of $19.04. The company has a fifty day moving average of $13.92 and a two-hundred day moving average of $14.00.

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.